ORIGINAL ARTICLE

Neuregulin-2 ablation results in dopamine dysregulation and severe behavioral phenotypes relevant to psychiatric disorders

L Yan[1,4,5], A Shamir[1,4,6], M Skirzewski[1,4], E Leiva-Salcedo[1,7], OB Kwon[1,8], I Karavanova[1], D Paredes[1,9], O Malkesman[2,10], KR Bailey[3,11], D Vullhorst[1], JN Crawley[3,12] and A Buonanno[1]

Numerous genetic and functional studies implicate variants of Neuregulin-1 (NRG1) and its neuronal receptor ErbB4 in schizophrenia and many of its endophenotypes. Although the neurophysiological and behavioral phenotypes of *NRG1* mutant mice have been investigated extensively, practically nothing is known about the function of NRG2, the closest NRG1 homolog. We found that NRG2 expression in the adult rodent brain does not overlap with NRG1 and is more extensive than originally reported, including expression in the striatum and medial prefrontal cortex (mPFC), and therefore generated NRG2 knockout mice (KO) to study its function. NRG2 KOs have higher extracellular dopamine levels in the dorsal striatum but lower levels in the mPFC; a pattern with similarities to dopamine dysbalance in schizophrenia. Like ErbB4 KO mice, NRG2 KOs performed abnormally in a battery of behavioral tasks relevant to psychiatric disorders. NRG2 KOs exhibit hyperactivity in a novelty-induced open field, deficits in prepulse inhibition, hypersensitivity to amphetamine, antisocial behaviors, reduced anxiety-like behavior in the elevated plus maze and deficits in the T-maze alteration reward test—a task dependent on hippocampal and mPFC function. Acute administration of clozapine rapidly increased extracellular dopamine levels in the mPFC and improved alternation T-maze performance. Similar to mice treated chronically with *N*-methyl-D-aspartate receptor (NMDAR) antagonists, we demonstrate that NMDAR synaptic currents in NRG2 KOs are augmented at hippocampal glutamatergic synapses and are more sensitive to ifenprodil, indicating an increased contribution of GluN2B-containing NMDARs. Our findings reveal a novel role for NRG2 in the modulation of behaviors with relevance to psychiatric disorders.

Molecular Psychiatry (2018) **23,** 1233–1243; doi:10.1038/mp.2017.22; published online 21 March 2017

INTRODUCTION

The Neuregulins (NRG 1–4) and their cognate neuronal receptor ErbB4 are among the numerous genetic variants associated with a risk for schizophrenia[1–4] and many of its endophenotypes.[5] Moreover, studies using human induced pluripotent stem cells from affected subjects,[6] as well as work in mice with targeted mutations in NRG1[7–9] and ErbB4,[10] provide strong experimental evidence for 'biological plausibility' of this pathway in psychiatric disorders.[11] Most psychiatric diseases, such as attention-deficit hyperactivity disorder (ADHD) and schizophrenia, manifest during development and exhibit a high degree of heritability. Although current pharmacological interventions for ADHD and schizophrenia target the dopamine system, multiple neurotransmitter systems including dopamine, glutamate, GABA and acetylcholine have been implicated in their pathophysiology.

The different regional, temporal and cellular expression patterns of NRG isoforms in the brain suggest distinct and non-overlapping functions. NRG1 transcripts are abundantly expressed in the embryonic and fetal brain but become restricted during postnatal development,[12] whereas NRG2 transcript levels markedly increase shortly after birth, suggesting important functions in the postnatal and adult brain.[13] In the hippocampus and neocortex, ErbB4 is confined to GABAergic interneurons,[14] and in the ventral tegmental area and substantia nigra compacta, ErbB4 is expressed in dopaminergic neurons[15,16] where it regulates activity from glutamatergic inputs.[17] NRG1 treatment acutely and markedly increases extracellular dopamine levels in behaving rats,[18] and regulates glutamatergic synaptic plasticity in acute hippocampal slices[19] and the power of gamma oscillations[20,21]—a type of local neuronal network activity associated with cognitive deficits in persons with psychiatric disorders.[22] Most, if not all, NRG effects are abolished in ErbB4 knockout mice (KO).[10] Consistent with these findings, ErbB4 KOs exhibit altered excitation/inhibition balance and numerous deficits

in behavioral tasks modeling schizophrenia and its endopheno-types, including prepulse inhibition (PPI; somatosensory gating), rewarded T-maze alternation (requires working memory) and social interactions.[7–10]

Despite its prominent expression in the postnatal and adult brain, little is known about NRG2 function and its potential involvement in neurodegenerative and neuropsychiatric disorders. Children with *de novo* overlapping 5q31 microdeletions,

encompassing three genes that include *NRG2*, share clinical features that include white matter abnormalities and severe developmental and intellectual delays.[23,24] Although the region encompassing the *NRG2* locus (5q23–33) has been associated with risk for schizophrenia[25–28] and genetically linked with ADHD in genome-wide scans of multigenerational extended families,[29] at the present time, genetic studies implicating this locus in psychiatric disorders is less compelling than for NRG1 signaling.

Functionally, like NRG1, a peptide harboring the NRG2 epidermal growth factor-like domain acutely promotes the internalization of $GABA_A Rs$[30] and *N*-methyl-D-aspartate receptors (NMDARs)[31] in hippocampal and cortical ErbB4-expressing GABAergic interneurons, respectively. NMDAR- and NRG2/ErbB4-dependent signaling pathways form a negative feedback loop in GABAergic interneurons in which NMDAR activity is required for NRG2 ectodomain shedding and subsequent activation of ErbB4 which in turn downregulates GluN2B-containing NMDARs.[31] The fact that NRG2 modulates glutamatergic transmission in GABAergic neurons and selectively affects GluN2B-containing NMDARs, a major proposed target of ketamine and the co-agonist glycine that lies at the heart of the hypoglutamatergic theory of schizophrenia,[32–34] raises the intriguing possibility that NRG2 could regulate brain development and neuronal circuits implicated in psychiatric disorders.

Here, we have generated KO mice to investigate a role for NRG2 in several psychiatrically relevant behavioral paradigms, dopamine balance and glutamatergic transmission. We believe this is the first study to analyze NRG2 functions *in vivo*, and to identify its importance for regulating dopaminergic and glutamatergic transmission and numerous behaviors associated with psychiatric diseases. As discussed, these findings warrant a renewed effort to investigate the possible association of *NRG2* variants with psychiatric disorders.

MATERIALS AND METHODS

Generation of NRG2 Kos
NRG2 KO mice were generated by recombineering (Figure 1e) and the targeted allele confirmed by Southern blot and PCR (see Supplementary Information for details). Mice were kept with food and water *ad libitum* on a 12/12 h light cycle. Procedures were performed in accordance with NIH Animal Welfare guidelines. As NRG2 heterozygote mice exhibited no phenotype in a number of tests (see Results), comparisons were between NRG2 KO and their corresponding non-mutant littermates called hereafter controls.

RNA in situ hybridization
In situ hybridization (ISH) experiments were performed on adult mouse brain sections (10–12 µm) using ^{33}P-labeled cRNA probes, as described,[13] or by triple RNAscope fluorescence using NRG1 or NRG2 probes paired with V-Glut-1 and GAD-1 probes (Cat-#s: 418181, 418191, 416631-C2,

400951-C3), according to the manufacturer's protocol (Advanced Cell Diagnostics, Newark, CA, USA).

Battery of behavior tests
Novelty-induced locomotor activity in the open field, PPI of startle, elevated plus maze and resident intruder tests were performed in adult littermates (14–18 week old), as described previously.[10] Amphetamine-induced (0–3 mg kg[−1]) locomotor activity and responses of NRG2 KO mice to clozapine were tested by initially habituating mice for 30 min to the open-field arena, administering the drug intraperitoneally and returning the mice to the same arena for measuring locomotor activity for 60 min. The rewarded T-maze consisted of a start arm and two identical goal arms with food wells at their ends. After training the animal to alternate between the arms, each mouse was given a free-choice run of 10 trials. Alternation rates were calculated as the percentage of correct entries of the total numbers of choice trials.

Electrophysiological slice recordings
Hippocampal slices (300 µm) from NRG2 KO and littermate control mice (4–6 weeks) were used to measure evoked excitatory postsynaptic currents (EPSCs) and long-term potentiation in whole-cell voltage-clamp mode as previously reported.[10,18] To determine the NMDA/AMPA ratio, neurons were stimulated at 50% of the maximal intensity in the presence of 100 µM picrotoxin to measure NMDAR currents at $V_h = +40$ mV (50 ms post stimulation artifact) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) currents at $V_h = -70$ mV. AMPA and NMDA *I/V* curves were derived by recording synaptic currents in the presence of 50 µM D-2-amino-5-phosphonovalerate acid or 10 µM CNQX, respectively, using a Multiclamp 700 A amplifier (Molecular Devices, Sunnyvale, CA, USA). Command voltage and current stimulus were controlled by pClamp 10.1 via a digital/analog interface (Digidata 1322A, Molecular Devices). The acquisition rate was 4 kHz and digitized at 20 kHz. Recorded data were analyzed with Sigmaplot software (Systat Software, Chicago, IL, USA).

Dopamine measurements
Extracellular dorsostriatal and medial prefrontal cortex (mPFC) dopamine was measured by microdialysis, followed by high performance liquid chromatography and electrochemical detection as described.[18] Microdialysis (2 mm probe, 18 kDa cutoff) was performed 1 week after guide cannulae implantation with continuous perfusion at 1 µl min[−1] for 1 h. Samples were collected every 15 min into 5 µl 0.1 M HCl+1 mM ethylenediaminetetraacetic acid and stored at −80 °C until analysis using an isocratic high performance liquid chromatography system with electrochemical detection. Quantification of extracellular and total dopamine was confirmed in independent samples by liquid chromatography, followed by mass spectrometry (Brains On-Line, San Francisco, CA).

RESULTS

Distinct expression patterns of NRG1 and NRG2 in the adult rodent brain
Earlier studies reported that NRG2 transcripts in the adult rodent brain are predominantly restricted to cerebellar, olfactory bulb

Figure 1. Expression patterns of NRG1 and NRG2 differ in the adult mouse brain. (**a**) ISH analyses for NRG1 and NRG2 were performed using either antisense ^{33}P-labeled cRNA probes (left) or RNAScope oligonucleotides probe sets (right). Representative low-magnification dark-field and fluorescence images of adult mouse coronal sections show differential regional expression of both NRGs in the habenula (HB), hippocampal dentate gyrus (DG) and CA1, thalamus (Th) and striatum (Str). Arrows indicate areas of highest NRG1 (HB) and NRG2 (DG) expression; open arrow indicates an emulsion artifact. (**b–d**) The distribution of NRG2 transcripts in glutamatergic and GABAergic neurons in the (**b**) prefrontal cortex (PFC), (**c**) hippocampus and (**d**) dorsal striatum were analyzed by triple ISH using RNAScope probes for NRG2 (white), vGlut (green) and GAD (magenta); nuclei were labeled with DAPI (blue). The middle and right panels correspond to the boxed area taken at higher magnification. Arrows indicate NRG2-expressing neurons, arrowheads mark neurons and presumably glial cells in the *corpus callosum* (cc) devoid of hybridization signal. Scale bar: 50 µm. (**e**) Diagram of the *Nrg2* region spanning exons 4–9 targeted by homologous recombination; targeted exons 5–8 shown in red (see Supplementary Information). (**f**) Western blots of cerebellar lysates from NRG2 KO and WT mice probed with antibodies against the extracellular (*ECD*) and intracellular (*ICD*) domains of NRG2. Arrow indicates the position of the pro-NRG2 band absent in NRG2 KOs. (**g**) Semiquantitative RT-PCR analysis reveals no compensatory changes in ErbB4, NRG1 and NRG3 mRNA levels in whole brain RNA preparations from adult NRG2 KO compared with wild-type littermate mice. Data are relative to β-actin and shown as means ± s.e.m. (*n* = 4 per group; *P* > 0.05 for all targets; Student's *t*-test). KO, knockout; WT, wild-type.

and hippocampal granule neurons.[13,35,36] Here we used more sensitive and independent ISH techniques, utilizing ^{33}P-labeled cRNA and fluorescent RNAScope probes (see Materials and Methods) to analyze NRG2 expression. As shown in Figure 1a, both radioactive (left) and fluorescence-based (right) approaches labeled the same regions for either the NRG1 or the NRG2 probes. As reported previously,[13,35,36] NRG2 ISH signals are strongest in hippocampal dentate gyrus granule cells; however, we also detected weaker signals in the neocortex, striatum and hippocampal CA1–CA3 neurons. By contrast, NRG1 expression is highest in cholinergic motor nuclei (not shown) and habenular nuclei (Figure 1a), consistent with a prior report,[12] and its overall regional expression pattern differs markedly from NRG2. Neuronal subtype-specific analyses in the mPFC (Figure 1b) and hippocampus (Figure 1c) using triple ISH labeling with RNAscope probes revealed that NRG2 is expressed in both Gad1-positive GABAergic neurons and vGlut-1-positive glutamatergic neurons, albeit at lower levels, as well as in most striatal medium spiny neurons (Figure 1d). RNAScope signals were not detected in mouse striatal sections hybridized with the DapB-negative control probe, and NRG1 and NRG2 probes yielded distinct patterns of positive and negative cells that were entirely devoid of signal (Supplementary Figure S1). The virtual absence of background labeling in RNAScope is consistent with prior studies.[37] These findings indicate that NRG2 is more widely expressed than originally reported and that its regional and temporal expression patterns differ from NRG1, suggesting distinct physiological functions for both ErbB receptor ligands.

Generation of NRG2 KO mice

The paucity of information about *in vivo* NRG2 functions prompted us to generate NRG2 KO mice by homologous recombination of exons 5–8 encoding the epidermal growth factor-like (α and β isoforms) and transmembrane domains (Figure 1e, see Supplementary Methods). Western blot analyses using antibodies against either the extracellular or the intracellular domains confirmed the lack of detectable NRG2 protein in brain extracts from NRG2 KO mice (Figure 1f). Furthermore, semiquantitative reverse transcription PCR revealed no significant compensatory effects of NRG2 deficiency on mRNA expression for NRG1, NRG3 and ErbB4 (Figure 1g). Mutant mice were viable but exhibited transient anatomical delays during early postnatal development that became insignificant after 5 weeks of age (Supplementary Figure S2), similar to a previously generated NRG2 KO line that only targeted exon 4 of the epidermal growth factor-like domain.[38] In our initial postnatal (birth to P21) basic behavioral assessment, NRG2 KO and wild-type (WT) littermates performed equally for negative geotaxis and cliff aversion, but showed a 1-day delay in eye opening, surface and air-righting

Figure 2. Hyperactivity of NRG2 KO mice is associated with elevated striatal dopamine and ameliorated by clozapine. (**a**) Novelty-induced locomotor activity in the open field during the 30-min observation period was consistently higher in NRG2 KO mice compared with their WT littermate controls. Data binned at 5 min intervals (*n* = 15 for each group). (**b**) Cumulative distance plot for data shown in (**a**). (**c, d**) Extracellular dopamine levels (**c**) and total dopamine content (**d**) in NRG2 KO mice and WT littermate controls. Measurements for extracellular dopamine were performed using microdialysis in freely moving mice (*n* = 4–5 per genotype; unpaired two-tailed Student's *t*-test). (**e**) Following habituation, clozapine treatment (1 mg kg^{-1}, i.p.) restored normal locomotor activity in NRG2 KO mice, but was without effect in WT littermates (*n* = 5–7 per genotype). Results represent the mean ± s.e.m., *$P < 0.05$, **$P < 0.01$ and ***$P < 0.0001$. KO, knockout; WT, wild-type.

reflexes, auditory startle and negative geotaxis, all of which normalized by the second week of postnatal development. No differences in size or neonatal measures were observed between NRG2 heterozygotes and WT littermates at any time during development (Supplementary Figure S2A). Moreover, no gender differences between adult NRG2 heterozygotes and WT littermates were observed in locomotor activity (Supplementary Figure S2B,C) or in the elevated plus maze (Supplementary Figure S2D,E); therefore, all subsequent comparisons were between NRG2 KOs and their control WT littermates.

NRG2 null mice have elevated striatal dopamine levels and exhibit increased locomotor activity

The expression of NRG2 in medium spiny neurons and the mPFC prompted us to test for spontaneous, novelty-induced activity in the open field (Figures 2a and b). Both mutants and controls habituated to the novel environment, but NRG2 KO mice were more active during the entire observation period ($F_{1,82} = 23.93$, $P < 0.0001$; two-way analysis of variance) and covered a significantly longer total distance (9019 ± 608 vs 6602 ± 560 cm; $t_{26} = 2.87$, $P < 0.01$). Because the marked increase of locomotor activity suggested altered dopamine neurotransmission, we used microdialysis to measure extracellular dopamine (Figure 2c) and its metabolites (Supplementary Table S1) in the dorsal striatum of freely moving mice (see Supplementary Methods). Indeed, we found that dopamine levels were approximately twofold higher in NRG2 KOs relative to controls (10.82 ± 0.82 vs 4.86 ± 0.30 nM, $t_8 = 6.81$, $P < 0.0001$). Consistent with the notion that extracellular dopamine levels in the dorsal striatum are regulated predominantly by DAT, homovanillic acid levels did not differ between genotypes (Supplementary Table S1), whereas DOPAC levels were ~1.8-fold higher in the NRG2 KOs relative to controls (9.3 ± 1.0 vs 5.2 ± 0.2 μM, $P < 0.01$). Of note, total striatal dopamine content was not different between mutant and control mice (Figure 2d), suggestive of an effect of NRG2 deficiency on modulation of dopamine release or uptake (see Discussion).

Positive symptoms in schizophrenia are associated with increases in striatal dopamine release (see ref. 39). The atypical antipsychotic clozapine, when administered acutely but not chronically,[40] can ameliorate dopamine dysbalance and behaviors in animal models.[40,41] Indeed, clozapine (1 mg kg^{-1}; intraperitoneal) restored normal locomotor activity of NRG2 mutants when injected 25 min prior to the open-field test (clozapine: 4565 ± 884 vs vehicle: 8255 ± 964 cm; $t_7 = 3.36$; $P < 0.05$; Figure 2e), such that the total distance traveled was similar to vehicle- or clozapine-treated WT controls (vehicle: 4444 ± 670 cm or clozapine: 3595 ± 369 cm; $t_9 = 0.097$; $P > 0.05$). Importantly, the lack of a clozapine effect on WT controls suggests that restoration of normal locomotor activity in hyperactive NRG2 KO mice is not due to generalized sedation (Figure 2e).

Reduced levels of mPFC dopamine and impaired working memory in NRG2 null mice

Functional imaging studies have repeatedly shown that mesostriatal and mesocortical/extrastriatal dopaminergic activity are inversely affected in schizophrenia.[39,42] Because striatal extracellular dopamine levels are elevated in NRG2 KOs (Figure 2c), we measured baseline dopamine levels in the mPFC and determined performance in a working memory task (Figure 3). Strikingly, we found that extracellular dopamine concentrations are significantly reduced in the mPFC of NRG2 KOs relative to littermate controls (0.40 ± 0.02 vs 0.98 ± 0.08 nM; $t_8 = 8.513$, $P < 0.0001$; Figure 3a). Homovanillic acid levels were also reduced (Supplementary Table S1), consistent with decreased dopamine availability for turnover by catechol-O-methyltransferase.

Numerous primate and rodent studies indicate that working memory performance relies on optimal dopamine levels in the

Figure 3. NRG2 null mice exhibit working memory deficits and reduced dopamine levels that are restored by acute clozapine administration. (**a**) Reduced extracellular dopamine levels in the mPFC of NRG2 KO mice ($n = 4$ per genotype; unpaired two-tailed Student's t-test). (**b**) Poor performance of NRG2 KO mice in a T-maze reward alternation task as compared with WT littermates (left) can be restored by clozapine (1 mg kg^{-1}, i.p.) administration (right; $n = 7$ per genotype) (two-way ANOVA with Sidak's post hoc test). (**c**) Extracellular dopamine levels in the mPFC of NRG2 KO mice ($n = 5$) and WT littermates ($n = 5$) before and after injection (arrowhead) of clozapine (two-way ANOVA for repeated measures with Sidak's test for multiple comparison for post hoc analysis). Dotted line demarks basal dopamine concentration in controls prior to injection. Results represent the mean $\pm$ s.e.m., **$P < 0.01$. KO, knockout; mPFC, medial prefrontal cortex; WT, wild-type.

dorsolateral prefrontal cortex,[43] with low levels suggested to reduce signal-to-noise ratios during cognitive tasks.[44] We therefore tested the performance of NRG2 KOs in the T-maze rewarded alternation task to assess working memory. As shown in Figure 3b (left), the percent of correct entries was lower for NRG2 KOs than for their WT littermates ($68 \pm 2.9\%$ vs $79 \pm 1.9\%$, $P < 0.01$, Sidak's post hoc test). Because acute clozapine administration can increase mPFC dopamine levels in rodents,[40] we investigated if clozapine (1 mg kg^{-1}, intraperitoneal) could improve performance of NRG2 KOs when administered 30–45 min before the task. As shown in Figure 3b (right), clozapine indeed improved task performance in drug-treated relative to vehicle-treated NRG2 KOs ($79 \pm 0.8\%$ vs $68 \pm 2.9\%$, $P < 0.01$). Importantly, rates of correct entries were not significantly different between clozapine-treated NRG2 KOs ($79 \pm 0.82\%$) and vehicle- ($79 \pm 1.9\%$) or clozapine-treated ($81 \pm 1\%$) WT littermates (significance for clozapine treatment: $F_{1,24} = 9.352$, $P < 0.01$, two-way analysis of variance). To determine whether cortical dopamine levels correlated with these behavioral findings, we measured extracellular concentrations in the mPFC of NRG2 KO and control littermates before and following clozapine treatment (Figure 3c). Interestingly, we found that clozapine steadily increased extracellular dopamine concentration up to 45 min post-injection in both controls (from 1.01 ± 0.07 to 2.03 ± 0.22 nM; $t_6 = 4.04$, $P < 0.005$) and NRG2 KOs

1238

(from 0.38 ± 0.03 to 1.38 ± 0.13 nM; $t_6 = 7.46$, $P < 0.0005$), the latter leveling off 45 min post-injection ($F_{1,6} = 28.92$, $P = 0.0017$). Notably, dopamine concentrations in NRG2 KOs between 30 and 45 min post-injection (when the T-maze task was performed) were near baseline levels in control mice. In summary, NRG2 KOs are hyperdopaminergic in the striatum and hypodopaminergic in the mPFC, and respond to acute clozapine treatment by elevating mPFC dopamine levels that correlate with improved working memory performance.

NRG2 KO mice exhibit multiple behavioral deficits associated with psychiatric disorders

Based on the observed dopamine dysbalance, as well as the genetic and functional association of the NRG-ErbB4 signaling pathway with schizophrenia[1–4] and its endophenotypes,[5] we assessed NRG2 KOs in rodent behavioral tasks with relevance to psychiatric disorders and reported to be altered in ErbB4 KO mice, including tests for amphetamine (Amph) sensitivity, sensorimotor gating, social interactions and anxiety-like behaviors.[45]

Individuals with schizophrenia manifest an augmented release of striatal dopamine (see ref. 39) and a subgroup exhibits higher sensitivity to psychosis induced by stimulants such as Amph,[46–48] whereas a large percentage of ADHD subjects exhibit a reduction in activity at higher psychostimulant doses.[49] To investigate if NRG2 KO mice are hypersensitive to psychostimulants or instead reduce their activity at higher Amph levels, we first performed a dose–response experiment ($0.0–3.0$ mg kg^{-1}; intraperitoneal) to determine the threshold for Amph-mediated stimulation of locomotor activity in WT mice habituated in an open-field chamber (Supplementary Figure S3). Based on this analysis, we then chose to test the effects of vehicle, 0.5 (subthreshold) and 3.0 mg kg^{-1} (suprathreshold) Amph on locomotor activity of NRG2 KO mice and their WT littermates after they were habituated to the open area. As shown in Figure 4a (left), total distance traveled approximately doubled following injection of 0.5 mg kg^{-1} Amph compared with vehicle-injected NRG2 KO mice (14146 ± 1090 vs 7363 cm ± 268 $P < 0.001$), whereas the same dose had no effect on WT littermates ($F_{3,36} = 51.03$, $P < 0.0001$; one-way analysis of variance). On the other hand, 3.0 mg kg^{-1} Amph increased the total distance traveled in both NRG2 KO and WT littermates by ~ 2.5-fold relative to their respective vehicle-injected controls (Figure 4a, right), indicating that both cohorts can respond to Amph but only NRG2 KO mice exhibit hypersensitivity to this psychostimulant.

PPI of the acoustic startle response, which is conserved across species, is a robust sensorimotor gating reflex that is regulated by dopamine and impaired in schizophrenia and potentially other psychiatric disorders.[50,51] Prompted by our observation of elevated striatal dopamine levels in NRG2 KOs, we measured the acoustic startle response and PPI in mutant and control mice. No genotype effect on acoustic startle was observed in response to a 120 dB sound (Figure 4b, left). Inhibition of the startle response increased with increasing prepulse acoustic intensities in both NRG2 KOs and controls, but was lower in NRG2 KOs ($F_{1,32} = 5.53$, $P < 0.05$). PPI was significantly lower across all sound intensity levels in NRG2 KO mice compared with WT littermate controls (Figure 4b, right; $F_{3,96} = 12.50$, $P < 0.0001$); no interaction between genotype and prepulse intensity was found.

We examined NRG2 KOs for social interaction behaviors, testing for aggression by scoring the frequency of approaches, tail rattling, biting and latency to attack using a resident intruder test (Figure 4c). The number of side approaches by NRG2 KO mice toward an intruder was significantly reduced compared with WT controls (12 ± 1.5 vs 19 ± 2.9; $t_{23} = 2.06$, $P < 0.05$), whereas olfactory investigation time was not different (134.3 ± 22.7 s vs 128.5 ± 28.2 s; data not shown). NRG2 KOs also displayed more tail rattling (2.5 ± 0.9 vs 0 ± 0; $t_{23} = 2.49$ $P < 0.05$) and attack bites (7.9 ± 2.7 vs 0.9 ± 0.6; $t_{23} = 2.35$ $P < 0.05$), and a reduced latency to attack (151 ± 77 vs 371 ± 47 s; $t_{23} = 2.42$, $P < 0.05$). These data indicate that NRG2 KO mice are aggressive and socially impaired.

Based on our earlier behavioral studies indicating that ErbB4 KO mice exhibit reduced anxiety-like behaviors,[10] we analyzed the preference of NRG2 KO mice for the open vs closed arms of an elevated plus-shaped maze (Figure 4d) as a measure commonly attributed to reduced anxiety-like or increased risk-taking behavior.[52] We found that NRG2 KOs enter into the open arms more often than controls (left; 53 ± 3 vs $31 \pm 4\%$; $t_{12} = 4.78$, $P < 0.0005$). In addition, NRG2 KOs spent more time in the open arms relative to controls (32 ± 5 vs $11 \pm 5\%$; $t_{12} = 3.25$, $P < 0.005$), whereas controls spent significantly more time exploring the closed arms (68 ± 4 vs $42 \pm 4\%$; $t_{12} = 4.54$, $P < 0.0005$); we observed no freezing behavior during exploration of the open arms by either genotype. Taken together with our earlier study,[10] these results suggest that NRG2 signaling through ErbB4 receptors in the adult brain may account, at least in part, for altered anxiety-related or risk-taking behaviors.

Analysis of NRG2 KO effects on neurotransmission and plasticity at glutamatergic synapses

NRG/ErbB4 signaling regulates glutamatergic transmission and plasticity at hippocampal Schaeffer collateral-to-CA1 (SC-CA1) synapses on pyramidal neurons that lack ErbB4[14] through an indirect mechanism that requires ErbB4 in GABAergic interneurons[10,53] and dopamine signaling.[18] Of note, we recently showed that NRG2 promotes the association of ErbB4 with GluN2B-containing NMDARs and downregulates NMDAR EPSCs in acute mPFC slices.[31] Moreover, because chronic NMDAR antagonist treatment in rodents paradoxically augments synaptic NMDAR currents,[54] resulting in dopamine imbalance,[32] and because dopamine modulates NMDAR kinetics and levels[55] (see Discussion), we investigated if dopamine dysregulation in NRG2 KO mice affects glutamatergic transmission and plasticity.

We began by analyzing current–voltage (I/V) relationships for AMPARs and NMDARs in adult acute hippocampal slices by recording EPSCs at SC-CA1 synapses. Whereas AMPAR I/V curves for NRG2 KOs and controls were linear and indistinguishable (Figure 5a), we found a profound difference in the NMDAR I/V relationship at positive potentials ranging from +20 to +80 mV (Figure 5b). In separate experiments, NMDAR EPSCs were recorded at +40 mV holding potential (V_h) in the presence of the AMPAR inhibitor CNQX (10 μM), and AMPAR were measured at − 70 mV in the presence of the NMDAR inhibitor D-2-amino-5-phosphonova-lerate acid (50 μM) to avoid potential contaminating currents (Figure 5c). Peak NMDAR currents in NRG2 KOs were 2.3-fold higher than in littermate controls (206.4 ± 30.7 vs 88.3 ± 39.5 pA; $P < 0.01$), whereas AMPAR currents did not differ between genotypes (-157.3 ± 51.0 vs -190.8 ± 21.1 pA; $P > 0.05$). Therefore, the marked increase in the NMDAR/AMPAR ratio in NRG2 KOs relative to controls (Figure 5d; 1.80 ± 0.46 vs 0.45 ± 0.03; $P < 0.001$) is driven by an increase in NMDAR EPSCs.

Amplitude and kinetics of NMDAR-mediated postsynaptic currents are largely dependent on GluN2 subunit composition, which is regulated during development and by dopamine signaling.[55] Whereas perinatal hippocampal SC-CA1 synapses mostly contain heterodimeric GluN1-GluN2B receptors, they are replaced during postnatal development by GluN1–GluN2A or heterotrimeric GluN1–GluN2A/2B receptors that have faster inactivation kinetics. To test whether increased NMDAR-mediated currents in NRG2 KOs are accompanied by an increase of GluN2B-containing receptors, we investigated the effects of two structurally independent antagonists (ifenprodil and Ro 25-6891) selective for heterodimeric GluN2B-containing receptors. We found that 3 μM ifenprodil (Figure 5e) did not significantly alter

Figure 4. NRG2 mutant mice exhibit numerous behavioral deficits associated with endophenotypes in psychiatric disorders. (**a**) Both control (black) and NRG2 KO (red) habituated mice display increased motor activity in response to 3.0 mg kg^{-1} (i.p., right panels) of Amph (checkered), relative to vehicle-injected mice (solid color), whereas only NRG2 KOs exhibited hyperactivity following a subthreshold dose 0.5 mg kg^{-1} of Amph (left panels; $n = 10$ per genotype; one-way ANOVA). (**b**) Startle responses (left) are similar in adult NRG2 KO and littermate control mice. PPI, measured at 74, 78, 82 and 86 dB prepulse stimulus intensities (right), is reduced in NRG2 KO mice ($n = 15$–19 per genotype; repeated two-way ANOVA). (**c**) NRG2 KO mice display abnormal social interactions in the resident intruder task characterized by a reduced number of side approaches (left), and increased aggressiveness manifesting as increased frequency of tail rattling (middle) and attack bites, and decreased latency to attack (right; $n = 12$–13 per genotype; Student's t-test). (**d**) NRG2 KO mice exhibit reduced anxiety-like behavior in the elevated plus maze, entering more often (left) and spending more time (right) in the open arms than control littermates. Entries into the open arms are shown as a percentage of all entries, and time spent in the open arms is plotted as a percentage of the total observation time; time spent in the middle is not shown ($n = 6$–8 per genotype; Student's t-test). Results represent the mean ± s.e.m.; *$P < 0.05$, **$P < 0.005$ and ***$P < 0.0005$. KO, knockout; WT, wild-type.

NMDAR peak currents in adult slices of WT control mice (50.5 ± 1.9 vs 47.5 ± 2.2 pA), consistent with the predominance of GluN2A-containing NMDAR in the adult hippocampus, whereas it markedly reduced NMDAR EPSCs in slices from NRG2 KOs (190.0 ± 12.8 vs 102.0 ± 7.6 pA, $P < 0.01$). Essentially the same results were obtained with 0.3 μM Ro 25-6891 (Supplementary Figure S4). Therefore, the increased NMDAR synaptic currents in NRG2 KOs result, at least in part, from a larger proportion of GluN2B-containing postsynaptic NMDARs. Interestingly, as shown previously for NRG1,[19] application of a peptide encompassing the NRG2 epidermal growth factor-like domain 20 min following long-term potentiation induction also effectively depotentiates long-term potentiation at SC-CA1 synapses (Supplementary Figure S5) and, consistent with increased NMDAR currents in NRG2 KOs, we observed that during the initial 20 min following the induction of long-term potentiation it was transiently augmented in slices from

mutant mice relative to WT littermate controls (Figure 5f; NRG2 KO: 245 ± 33% vs WT, 175 ± 11%; $P < 0.0001$, Student's t-test).

DISCUSSION
Here we report for the first time that NRG2 KO mice exhibit a marked dopamine dysbalance in the dorsal striatum and mPFC, altered glutamatergic transmission in the hippocampus and numerous behavioral impairments, responsive to clozapine treatment, that phenocopy animal models for psychiatric disorders. These findings are relevant to identify NRG2 functions in the adult brain and have important implications for our understanding of how the NRG2-ErbB signaling pathway regulates dopamine balance, synaptic mechanisms and behaviors that underlie psychiatric disorders. As discussed below, the extensive overlap of behaviors altered in NRG2 and ErbB4 KO mice strongly

Figure 5. Altered NMDAR function and enhanced GluN2B activity in NRG2 KO mice. I–V curves of AMPAR- (**a**) and NMDAR-mediated currents (**b**) showing respective peak amplitudes obtained for voltage steps ranging from − 100 to +80 mV in slices from NRG2 KO (red) and littermate control (black) mice ($N = 5$ mice; $n = 5$ slices each for WT and NRG2 KOs). (**c**) Average amplitudes of AMPAR EPSCs at − 70 mV and NMDAR EPSCs at +40 mV (WT: $N = 5$, $n = 7$; KO: $N = 6$, $n = 9$). (**d**) NMDAR/AMPAR ratios in NRG2 KOs and littermate controls (plotted from data shown in (**c**). (**e**) Effects of the GluN2B-selective inhibitor ifenprodil on NMDAR-mediated currents in slices from NRG2 KOs (red) and WT littermate (black) mice. Ifenprodil did not significantly affect NMDAR currents in WT slices ($N = 5$; $n = 9$), but greatly reduced NMDAR currents in slices from NRG2 null mice ($N = 5$; $n = 6$; mean $\pm$ s.e.m.,**$P < 0.01$). (**f**) Hippocampal slices from NRG2 KO mice exhibit transiently increased LTP compared with slices from littermate controls (NRG2 KO: $N = 4$, $n = 6$; WT: $N = 4$, $n = 7$, mean $\pm$ s.e.m., **$P < 0.001$). AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; EPSC, excitatory postsynaptic currents; KO, knockout; NMDAR, N-methyl-D-aspartate receptor; WT, wild-type.

suggests that NRG2 is a major ErbB4 ligand in the adult brain affecting dopaminergic and glutamatergic functions.

Association of the NRG/ErbB4 signaling pathway with psychiatric disorders

There is accumulating genetic and functional evidence for an involvement of the NRG/ErbB4 signaling pathway in the etiology of schizophrenia and other psychiatric disorders.[1–4] Postmortem brain studies from subjects with schizophrenia and matched controls reported increased NRG1 and NRG3 mRNA levels,[56,57] altered expression of ErbB4 splice variants[58,59] and enhanced NRG/ErbB4 signaling.[60] Polymorphic variants of NRG1, NRG3 and ErbB4 are also associated with heritable schizophrenia endophenotypes, including reduced PPI, altered frontal and temporal lobe activity and working memory deficits.[5,61] Genome-wide scans have identified a region that encompasses the NRG2 locus (5q31.2) that is linked to multigenerational extended families with ADHD,[29] and associated with schizophrenia[25–28] and bipolar disorder.[62] A novel syndrome identified in seven children with de novo overlapping 5q31 microdeletions that encompass three genes (including NRG2) share clinical features that include white matter abnormalities, affecting frontal lobes, severe developmental and intellectual delays, feeding difficulties and seizures.[23,24] Of note, the NRG/ErbB signaling pathway regulates peripheral myelination, and two independent NRG2 KO lines display early growth retardation[38] (Supplementary Figure S2); we also observed

that NRG2 KO pups suckle less effectively than littermates and may experience transient neonatal seizures (unpublished observations).

Some of the behavioral deficits observed in NRG2 KOs overlap with those of NRG1 hypomorphs (NRG1 KOs die at E10.5), including locomotor hyperactivity and PPI deficits responsive to clozapine;[7,9] in addition, NRG1 (type III) heterozygotes have reduced short-term memory and spatial memory that are improved by nicotine.[8] However, our NRG2 null mice exhibit additional behavioral anomalies that were not reported in NRG1 hypomorphs, such as reduced anxiety-like behavior and increased sensitivity to psychostimulants. These phenotypic differences are consistent with the distinct regional and temporal expression patterns of NRG1 and NRG2. In contrast to NRG1, NRG2 expression increases postnatally and is detected at relatively high levels in striatal medium spiny and neocortical neurons (Figure 1). Importantly, ErbB4 is expressed in mesencephalic dopaminergic neurons that project to the striatum, mPFC and hippocampus that are regulated by NRG.[15–17] Interestingly, ErbB4 null mice exhibit many of the behavioral abnormalities that we have observed in NRG2 KOs[10] and that are absent in NRG1 mutants (see above), suggesting that these behaviors are regulated by NRG2/ErbB4 signaling. Moreover, NRG2 KOs phenocopy the augmented striatal dopamine levels, Amph hypersensitivity and behavioral deficits reported for rodent lesion models[63,64] and other genetically targeted models of schizophrenia endophenotypes,[65–70] suggesting a potential convergence of

mechanisms that regulate neuronal circuits underlying core disease traits.

Dysbalance of dopaminergic and glutamatergic pathways in NRG2 KOs and its relevance to psychiatric disorders

NRG2 deficiency affects mPFC and striatal extracellular dopamine concentrations in opposite directions. This finding is reminiscent of functional imaging studies in persons with schizophrenia reporting pathway-specific dopamine dysfunction in the striatal pathway (hyperdopaminergia) and subcortical-extrastriatal and cortical pathways (hypodopaminergia),[39] as well as reduced dopamine release in the dorsolateral prefrontal cortex during a working memory task.[42] Consistent with increased striatal dopamine levels, NRG2 KO mice have reduced PPI and exhibit hyperactivity in the open field that is ameliorated by acute clozapine treatment. Interestingly, acute clozapine administration also improved performance in the rewarded T-maze task, which requires working memory, and correlated with increased mPFC dopamine levels in NRG2 KOs. Improved T-maze performance may appear paradoxical, based on the ineffectiveness of clozapine to improve negative symptoms and cognitive deficits in schizophrenia.[71] However, early improvements (24 h) in core schizophrenia symptoms in response to antipsychotics have been reported[72] (also see ref. 32), and in animal studies acute, but not chronic, clozapine administration increased mPFC dopamine levels.[40] Based on prior rodent and non-human primate studies, clozapine may have improved NRG2 KO performance on the rewarded T-maze either by indirectly augmenting D1R signaling via increased dopamine levels,[55] by directly blocking excessive activity of D4Rs[21,73,74] (which are functionally coupled to ErbB4 receptors on parvalbumin-positive interneurons and regulate gamma oscillations[21]), or by simultaneously activating D1- and D2-type receptors to optimize temporal gating.[73,74]

NRG2 deficiency also markedly increases hippocampal NMDAR currents (Figure 5). The observation that NMDAR antagonists phencyclidine and ketamine can elicit behaviors in healthy volunteers that resemble positive, negative and cognitive symptoms initially led to the NMDAR hypofunction hypothesis in schizophrenia. However, the effects of NMDAR antagonists and their cellular site of action are paradoxical.[33] Chronic NMDAR antagonist treatment facilitates synaptic NMDAR currents[54] and increases GluN1 and GluN2B mRNA expression.[65] Acutely, NMDAR antagonists increase, rather than decrease, cortical excitation and the power of unevoked gamma oscillations—a type of neuronal network activity associated with working memory.[33] NMDAR antagonists could affect cortical excitability directly by diminishing excitatory drive onto GABAergic interneurons,[75] or indirectly by increasing the activity of cortico-mesencephalic pathways that augment mPFC dopamine levels.[76] The latter mechanism is important because dopamine is known to modulate NMDAR kinetics and synaptic levels,[55] as we observed in NRG2 KOs. Moreover, chronic administration of NMDAR antagonists elicits many behavioral changes that phenocopy those observed in NRG2 KOs, such as increased sensitivity to stress and Amph-induced hyperactivity, working memory impairments, decreased social interactions and increased locomotor activity (the latter can however occur independently of dopamine changes[77]). Therefore, the dysregulation of dopamine and NMDAR signaling and altered behaviors in NRG2 KO mice could result from perturbations of the intricate bi-directional interactions between the glutamatergic and dopaminergic signaling pathways that may converge on common neuronal circuits that modulate these behaviors (see ref. 32). Recently, Rosen et al.[70] used the term 'electrophysiological endophenotypes' to describe how a variety of rodent models of psychosis and schizophrenia targeting widely different risk factors nevertheless exhibit similar core electrophysiological properties.

Although the question of a direct role of NRG2 in the etiology of psychiatric disorders remains to be determined, the NRG2 KO mice reported here constitute an excellent model to dissect the roles of neurotransmitters and microcircuits that have been implicated in behavioral and electrophysiological endopheno-types relevant to several neuropsychiatric disorders, as well as drug abuse and addiction.[78] This is especially pertinent considering the behavioral phenotypes and alterations in dopamine and glutamate transmission reported here, the fact that ErbB4 signaling in the hippocampus and mPFC is restricted to GABAergic neurons and regulates plasticity and neuronal network oscillations through fast-spiking parvalbumin-positive interneurons, and our recent finding of a negative feedback loop between NMDARs and NRG2/ErbB4 signaling in GABAergic interneurons.[31] The fact that NRG2 regulates glutamatergic transmission in GABAergic neurons and selectively affects GluN2B-containing NMDARs (this study,[31]), potentially an important extrasynaptic receptor subtype affecting tonic glutamatergic transmission and a major proposed target of ketamine,[34,79] raises the intriguing possibility that alterations in NRG2 levels could regulate numerous pathways and circuits implicated in several neuropsychiatric disorders.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

1 Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005; 10: 40–68.

2 Buonanno A. The neuregulin signaling pathway and schizophrenia: from genes to synapses and neural circuits. Brain Res Bull 2010; 83: 122–131.

3 Mei L, Nave KA. Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases. Neuron 2014; 83: 27–49.

4 Mostaid MS, Lloyd D, Liberg B, Sundram S, Pereira A, Pantelis C et al. Neuregulin-1 and schizophrenia in the genome-wide association study era. Neurosci Biobehav Rev 2016; 68: 387–409.

5 Greenwood TA, Light GA, Swerdlow NR, Radant AD, Braff DL. Association analysis of 94 candidate genes and schizophrenia-related endophenotypes. PLoS ONE 2012; 7: e29630.

6 Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011; 473: 221–225.

7 Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002; 71: 877–892.

8 Chen YJ, Johnson MA, Lieberman MD, Goodchild RE, Schobel S, Lewandowski N et al. Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J Neurosci 2008; 28: 6872–6883.

9 O'Tuathaigh CM, Babovic D, O'Sullivan GJ, Clifford JJ, Tighe O, Croke DT et al. Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. Neuroscience 2007; 147: 18–27.

10 Shamir A, Kwon OB, Karavanova I, Vullhorst D, Leiva-Salcedo E, Janssen MJ et al. The importance of the NRG-1/ErbB4 pathway for synaptic plasticity and behaviors associated with psychiatric disorders. J Neurosci 2012; 32: 2988–2997.

11 Neddens J, Fish KN, Tricoire L, Vullhorst D, Shamir A, Chung W et al. Conserved interneuron-specific ErbB4 expression in frontal cortex of rodents, monkeys, and humans: implications for schizophrenia. Biol Psychiatry 2011; 70: 636–645.

12 Corfas G, Rosen KM, Aratake H, Krauss R, Fischbach GD. Differential expression of ARIA isoforms in the rat brain. Neuron 1995; 14: 103–115.

13 Longart M, Liu Y, Karavanova I, Buonanno A. Neuregulin-2 is developmentally regulated and targeted to dendrites of central neurons. *J Compar Neurol* 2004; **472**: 156–172.

14 Vullhorst D, Neddens J, Karavanova I, Tricoire L, Petralia RS, McBain CJ et al. Selective expression of ErbB4 in interneurons, but not pyramidal cells, of the rodent hippocampus. *J Neurosci* 2009; **29**: 12255–12264.

15 Steiner H, Blum M, Kitai ST, Fedi P. Differential expression of ErbB3 and ErbB4 neuregulin receptors in dopamine neurons and forebrain areas of the adult rat. *Exp Neurol* 1999; **159**: 494–503.

16 Abe Y, Namba H, Zheng Y, Nawa H. In situ hybridization reveals developmental regulation of ErbB1-4 mRNA expression in mouse midbrain: implication of ErbB receptors for dopaminergic neurons. *Neuroscience* 2009; **161**: 95–110.

17 Ledonne A, Nobili A, Latagliata EC, Cavallucci V, Guatteo E, Puglisi-Allegra S et al. Neuregulin 1 signalling modulates mGluR1 function in mesencephalic dopaminergic neurons. *Mol Psychiatry* 2015; **20**: 959–973.

18 Kwon OB, Paredes D, Gonzalez CM, Neddens J, Hernandez L, Vullhorst D et al. Neuregulin-1 regulates LTP at CA1 hippocampal synapses through activation of dopamine D4 receptors. *Proc Natl Acad Sci USA* 2008; **105**: 15587–15592.

19 Kwon OB, Longart M, Vullhorst D, Hoffman DA, Buonanno A. Neuregulin-1 reverses long-term potentiation at CA1 hippocampal synapses. *J Neurosci* 2005; **25**: 9378–9383.

20 Fisahn A, Neddens J, Yan L, Buonanno A. Neuregulin-1 modulates hippocampal gamma oscillations: implications for schizophrenia. *Cereb Cortex* 2009; **19**: 612–618.

21 Andersson RH, Johnston A, Herman PA, Winzer-Serhan UH, Karavanova I, Vullhorst D et al. Neuregulin and dopamine modulation of hippocampal gamma oscillations is dependent on dopamine D4 receptors. *Proc Natl Acad Sci USA* 2012; **109**: 13118–13123.

22 Gonzalez-Burgos G, Cho RY, Lewis DA. Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia. *Biol Psychiatry* 2015; **77**: 1031–1040.

23 Hosoki K, Ohta T, Natsume J, Imai S, Okumura A, Matsui T et al. Clinical phenotype and candidate genes for the 5q31.3 microdeletion syndrome. *Am J Med Genetics A* 2012; **158A**: 1891–1896.

24 Shimojima K, Isidor B, Le Caignec C, Kondo A, Sakata S, Ohno K et al. A new microdeletion syndrome of 5q31.3 characterized by severe developmental delays, distinctive facial features, and delayed myelination. *Am J Med Genet A* 2011; **155A**: 732–736.

25 Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. *Am J Hum Genet* 2003; **73**: 34–48.

26 Schwab SG, Eckstein GN, Hallmayer J, Lerer B, Albus M, Borrmann M et al. Evidence suggestive of a locus on chromosome 5q31 contributing to susceptibility for schizophrenia in German and Israeli families by multipoint affected sib-pair linkage analysis. *Mol Psychiatry* 1997; **2**: 156–160.

27 Sklar P, Pato MT, Kirby A, Petryshen TL, Medeiros H, Carvalho C et al. Genome-wide scan in Portuguese Island families identifies 5q31-5q35 as a susceptibility locus for schizophrenia and psychosis. *Mol Psychiatry* 2004; **9**: 213–218.

28 Straub RE, MacLean CJ, O'Neill FA, Walsh D, Kendler KS. Support for a possible schizophrenia vulnerability locus in region 5q22-31 in Irish families. *Mol Psychiatry* 1997; **2**: 148–155.

29 Arcos-Burgos M, Castellanos FX, Pineda D, Lopera F, Palacio JD, Palacio LG et al. Attention-deficit/hyperactivity disorder in a population isolate: linkage to loci at 4q13.2, 5q33.3, 11q22, and 17p11. *Am J Hum Genet* 2004; **75**: 998–1014.

30 Mitchell RM, Janssen MJ, Karavanova I, Vullhorst D, Furth K, Makusky A et al. ErbB4 reduces synaptic GABAA currents independent of its receptor tyrosine kinase activity. *Proc Natl Acad Sci USA* 2013; **110**: 19603–19608.

31 Vullhorst D, Mitchell RM, Keating C, Roychowdhury S, Karavanova I, Tao-Cheng JH et al. A negative feedback loop controls NMDA receptor function in cortical interneurons via neuregulin 2/ErbB4 signalling. *Nat Commun* 2015; **6**: 7222.

32 Coyle JT, Basu A, Benneyworth M, Balu D, Konopaske G. Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. *Handb Exp Pharmacol* 2012; **213**: 267–295.

33 Moghaddam B, Krystal JH. Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. *Schizophr Bull* 2012; **38**: 942–949.

34 Balu DT, Coyle JT. The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond. *Curr Opin Pharmacol* 2015; **20**: 109–115.

35 Busfield SJ, Michnick DA, Chickering TW, Revett TL, Ma J, Woolf EA et al. Characterization of a neuregulin-related gene, Don-1, that is highly expressed in restricted regions of the cerebellum and hippocampus. *Mol Cell Biol* 1997; **17**: 4007–4014.

36 Carraway KL 3rd, Weber JL, Unger MJ, Ledesma J, Yu N, Gassmann M et al. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. *Nature* 1997; **387**: 512–516.

37 Rocco BR, Sweet RA, Lewis DA, Fish KN. GABA-synthesizing enzymes in calbindin and calretinin neurons in monkey prefrontal cortex. *Cereb Cortex* 2016; **26**: 2191–2204.

38 Britto JM, Lukehurst S, Weller R, Fraser C, Qiu Y, Hertzog P et al. Generation and characterization of neuregulin-2-deficient mice. *Mol Cell Biol* 2004; **24**: 8221–8226.

39 Weinstein JJ, Chohan MO, Slifstein M, Kegeles LS, Moore H, Abi-Dargham A. Pathway-specific dopamine abnormalities in schizophrenia. *Biol Psychiatry* 2016; **81**: 31–42.

40 Chen JP, Ruan D, Paredes W, Gardner EL. Effects of acute and chronic clozapine on dopaminergic function in medial prefrontal cortex of awake, freely moving rats. *Brain Res* 1992; **571**: 235–241.

41 Geyer MA, Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. *Prog Neuro-psychopharmacol Biol Psychiatry* 2003; **27**: 1071–1079.

42 Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. *JAMA Psychiatry* 2015; **72**: 316–324.

43 Aalto S, Bruck A, Laine M, Nagren K, Rinne JO. Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. *J Neurosci* 2005; **25**: 2471–2477.

44 Winterer G, Weinberger DR. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. *Trends Neurosci* 2004; **27**: 683–690.

45 Lipska BK, Weinberger DR. To model a psychiatric disorder in animals: schizophrenia as a reality test. *Neuropsychopharmacology* 2000; **23**: 223–239.

46 Lieberman JA, Kane JM, Sarantakos S, Gadaleta D, Woerner M, Alvir J et al. Prediction of relapse in schizophrenia. *Arch Gen Psychiatry* 1987; **44**: 597–603.

47 Koreen AR, Lieberman JA, Alvir J, Chakos M. The behavioral effect of m-chlorophenylpiperazine (mCPP) and methylphenidate in first-episode schizophrenia and normal controls. *Neuropsychopharmacology* 1997; **16**: 61–68.

48 Yui K, Goto K, Ikemoto S, Ishiguro T, Angrist B, Duncan GE et al. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. *Mol Psychiatry* 1999; **4**: 512–523.

49 Gowrishankar R, Hahn MK, Blakely RD. Good riddance to dopamine: roles for the dopamine transporter in synaptic function and dopamine-associated brain disorders. *Neurochem Int* 2014; **73**: 42–48.

50 Braff DL. Prepulse inhibition of the startle reflex: a window on the brain in schizophrenia. *Curr Top Behav Neurosci* 2010; **4**: 349–371.

51 Kohl S, Heekeren K, Klosterkotter J, Kuhn J. Prepulse inhibition in psychiatric disorders--apart from schizophrenia. *J Psychiatr Res* 2013; **47**: 445–452.

52 Bourin M, Petit-Demouliere B, Dhonnchadha BN, Hascoet M. Animal models of anxiety in mice. *Fundam Clin Pharmacol* 2007; **21**: 567–574.

53 Chen YJ, Zhang M, Yin DM, Wen L, Ting A, Wang P et al. ErbB4 in parvalbumin-positive interneurons is critical for neuregulin 1 regulation of long-term potentiation. *Proc Natl Acad Sci USA* 2010; **107**: 21818–21823.

54 Yu B, Wang C, Liu J, Johnson KM, Gallagher JP. Adaptation to chronic PCP results in hyperfunctional NMDA and hypofunctional GABA(A) synaptic receptors. *Neuroscience* 2002; **113**: 1–10.

55 Ladepeche L, Dupuis JP, Groc L. Surface trafficking of NMDA receptors: gathering from a partner to another. *Semin Cell Dev Biol* 2014; **27**: 3–13.

56 Hashimoto R, Straub RE, Weickert CS, Hyde TM, Kleinman JE, Weinberger DR. Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. *Mol Psychiatry* 2004; **9**: 299–307.

57 Kao WT, Wang Y, Kleinman JE, Lipska BK, Hyde TM, Weinberger DR et al. Common genetic variation in Neuregulin 3 (NRG3) influences risk for schizophrenia and impacts NRG3 expression in human brain. *Proc Natl Acad Sci USA* 2010; **107**: 15619–15624.

58 Silberberg G, Darvasi A, Pinkas-Kramarski R, Navon R. The involvement of ErbB4 with schizophrenia: association and expression studies. *Am J Med Genet B Neuropsychiatr Genet* 2006; **141B**: 142–148.

59 Joshi D, Fullerton JM, Weickert CS. Elevated ErbB4 mRNA is related to interneuron deficit in prefrontal cortex in schizophrenia. *J Psychiatr Res* 2014; **53**: 125–132.

60 Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, Berrettini WH et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. *Nat Med* 2006; **12**: 824–828.

61 Hall J, Whalley HC, Job DE, Baig BJ, McIntosh AM, Evans KL et al. A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. *Nat Neurosci* 2006; **9**: 1477–1478.

62 Zhao Z, Xu J, Chen J, Kim S, Reimers M, Bacanu SA et al. Transcriptome sequencing and genome-wide association analyses reveal lysosomal function and actin cytoskeleton remodeling in schizophrenia and bipolar disorder. *Mol Psychiatry* 2015; **20**: 563–572.

63 Lodge DJ, Grace AA. Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia. *Neurotox Res* 2008; **14**: 97–104.

64 Tseng KY, Chambers RA, Lipska BK. The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. *Behav Brain Res* 2009; **204**: 295–305.

65 Rujescu D, Bender A, Keck M, Hartmann AM, Ohl F, Raeder H et al. A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. *Biol Psychiatry* 2006; **59**: 721–729.

66 Dzirasa K, Ramsey AJ, Takahashi DY, Stapleton J, Potes JM, Williams JK et al. Hyperdopaminergia and NMDA receptor hypofunction disrupt neural phase signaling. *J Neurosci* 2009; **29**: 8215–8224.

67 Gainetdinov RR, Mohn AR, Bohn LM, Caron MG. Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. *Proc Natl Acad Sci USA* 2001; **98**: 11047–11054.

68 Lipina TV, Niwa M, Jaaro-Peled H, Fletcher PJ, Seeman P, Sawa A et al. Enhanced dopamine function in DISC1-L100P mutant mice: implications for schizophrenia. *Genes Brain Behav* 2010; **9**: 777–789.

69 Jaaro-Peled H, Hayashi-Takagi A, Seshadri S, Kamiya A, Brandon NJ, Sawa A. Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1. *Trends Neurosciences* 2009; **32**: 485–495.

70 Rosen AM, Spellman T, Gordon JA. Electrophysiological endophenotypes in rodent models of schizophrenia and psychosis. *Biol Psychiatry* 2015; **77**: 1041–1049.

71 Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS et al. What CATIE found: results from the schizophrenia trial. *Psychiatr Serv* 2008; **59**: 500–506.

72 Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. *Am J Psychiatry* 2005; **162**: 939–946.

73 Xu TX, Yao WD. D1 and D2 dopamine receptors in separate circuits cooperate to drive associative long-term potentiation in the prefrontal cortex. *Proc Natl Acad Sci USA* 2010; **107**: 16366–16371.

74 Furth KE, Mastwal S, Wang KH, Buonanno A, Vullhorst D. Dopamine, cognitive function, and gamma oscillations: role of D4 receptors. *Front Cell Neurosci* 2013; **7**: 102.

75 Rotaru DC, Yoshino H, Lewis DA, Ermentrout GB, Gonzalez-Burgos G. Glutamate receptor subtypes mediating synaptic activation of prefrontal cortex neurons: relevance for schizophrenia. *J Neurosci* 2011; **31**: 142–156.

76 Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. *J Neurosci* 1997; **17**: 2921–2927.

77 Cornish JL, Nakamura M, Kalivas PW. Dopamine-independent locomotion following blockade of N-methyl-D-aspartate receptors in the ventral tegmental area. *J Pharmacol Exp Ther* 2001; **298**: 226–233.

78 Javitt DC, Schoepp D, Kalivas PW, Volkow ND, Zarate C, Merchant K et al. Translating glutamate: from pathophysiology to treatment. *Sci Transl Med* 2011; **3**: 102mr102.

79 Miller OH, Yang L, Wang CC, Hargroder EA, Zhang Y, Delpire E et al. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. *eLife* 2014; **3**: e03581.

Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)